STOCK TITAN

Transmedics Group Inc - TMDX STOCK NEWS

Welcome to our dedicated news page for Transmedics Group (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Transmedics Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Transmedics Group's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.55%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.84%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24%
Tags
Transmedics Group Inc

Nasdaq:TMDX

TMDX Rankings

TMDX Stock Data

3.02B
31.55M
3.62%
111.73%
18.31%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Andover

About TMDX

transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.